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ABSTRACT 
Objective  
To identify the range and frequency of patient-reported barriers and facilitators to 
antiretroviral treatment (ART) adherence in Sub-Saharan Africa (SSA). 
Design 
Studies from 2005-2016 were identified by searching 10 electronic databases and 
through additional hand and web-searching.  
Methods 
Inclusion criteria were: HIV positive adults taking ART based in any SSA country, 
qualitative study or quantitative survey and included at least one patient-reported barrier 
or facilitator to ART adherence. Exclusion criteria were: only including data from 
treatment-naïve patients initiating ART, only single dose treatment, participants residing 
outside of SSA and reviews.  
Results 
After screening 11283 records, 154 studies (163 papers) were included in this review. 
Forty-three barriers and 30 facilitators were reported across 24 SSA countries. The most 
frequently identified barriers across studies were forgetting (n=76), lack of access to 
adequate food (n=72), stigma and discrimination (n=68), side effects (n=67) and being 
outside the house or travelling (n=60). The most frequently identified facilitators across 
studies were social support (n=60), reminders (n=55), feeling better or heathier after 
taking ART (n=35), disclosing their HIV status (n=26) and having a good relationship 
with a health provider (n=22).  
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Conclusions 
This review addresses the gap in knowledge by collating all the patient-reported barriers 
and facilitators to ART adherence in SSA. Current barriers measures need to be adapted 
or new tools developed to include the wide variety of factors identified. The factors that 
have the greatest impact need to be isolated so interventions are developed which 
reduce the barriers and enhance the facilitators.  
Key words: HIV, AIDS, Africa South of the Sahara, Antiretroviral Therapy, 
Medication adherence 
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INTRODUCTION 
Nearly 25 million people, 70% of all those living with HIV globally, live in countries in 
Sub-Saharan Africa (SSA) [1]. HIV is a debilitating disease; however, antiretroviral 
treatment (ART) helps promote effective viral suppression, reduces the risk of 
transmission and prevents death [2,3]. To ensure positive treatment outcomes, high 
levels of ART adherence (80-95%) are necessary depending on the regime potency [4-
6]; however a meta-analysis [7] indicated that 23% of Africans were achieving less than 
80% adherence, potentially impacting on prognosis.   
Mills and colleagues [3] conducted a systematic review in 2005 of patient-reported 
barriers and facilitators to ART adherence globally. This review identified important 
barriers, in both high income countries (HIC) and low and middle income countries 
(LMIC), which included substance abuse, forgetfulness, pill burden, fear of disclosure, 
falling asleep, decreased quality of life, access to medication, being suspicious of the 
treatment, work and family responsibilities and complicated regimens; however, only 
12 (14.3%) of the studies included were conducted in LMIC of which only five were in 
SSA. ART availability in SSA has improved since this review was conducted, with 1.3 
million patients receiving ART treatment in 2006; a 10-fold increase on patients with 
access three years earlier [8]. The lack of treatment availability would have impacted 
the number of studies being conducted in this region, which has steadily increased over 
the past decade.  
No facilitators were identified by Mills et al. in LMIC [3]; however, important 
facilitators were identified included seeing positive effects of medication, accepting 
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their HIV status, using reminders, having a simple regimen, sense of self-worth and 
understanding the need for strict adherence. Although some similarities were found 
between different settings and countries, the review urged the need to determine the 
patient-important factors for adherence in LMIC [3] due to the number of people living 
with HIV in these areas and the unique psycho-socio-political environments.  
In the past decade there has been a shift in simply identifying and reporting rates of 
non-adherence and an increased focus on identifying and addressing barriers and 
facilitators to ART adherence in LMIC, in particular in SSA [9-11]; therefore, this 
systematic review is a critical update. The review identifies adult patient-reported 
barriers and facilitators to ART adherence in SSA from 2005-2016 in studies with 
qualitative and quantitative methodology.  
METHODS 
Search Strategy 
The review was conducted in-line with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines (PRISMA) [12]. N.C. performed searches on 10 
databases on the 24
th
 May 2016: Cochrane Library, MEDLINE (OVID), PsycINFO 
(OVID), PsycARTICLES (OVID), EMBASE (OVID), Global Health (OVID), 
CINAHL (EBSCO), International Bibliography of the Social Science (IBSS; Proquest), 
Applied Social Sciences Index and Abstracts (AIDIA; Proquest) and African Index 
Medicus (AIM; WHO). Search terms were varied to adapt to the different requirements 
of the different databases. The search included terms related to HIV, ART, SSA 
countries and adherence (see supplementary material for full example of search 
strategy), http://links.lww.com/QAD/B44.  
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All databases were searched from 2005 to May 24
th
 2016 to investigate the research 
published since Mills and colleagues‘ review [3]. All records were downloaded into 
ENDNOTE (X7.4). 
Hand-searching, web-searching and forward citation searching were conducted to find 
other relevant published and unpublished studies. Abstracts from the following 
international conferences were searched: International AIDS Society (IAS; 2005-2015), 
Conference on Retroviruses and Opportunistic Infections (CROI; 2014, 2016), AIDS 
Impact (2009-2015) and International AIDS Conference (2006-2014). For all 
potentially relevant abstracts, if no published article was found the authors were 
contacted for more details if possible. Reference lists of included articles and systematic 
reviews were searched. Searches in Google Scholar were conducted using search terms 
such as ―adherence‖, ―HIV‖ and ―Sub-Saharan Africa‖. Forward tracking of Mills and 
colleagues‘ review [3] was also performed in the Web of Science database.  
Study Selection 
N.C. reviewed all the titles and abstracts of each record to assess potential relevance and 
M.Ah. examined a random sample (10%) and a concordance rate was measured. 
Acceptable concordance was predefined as agreement on at least 90% which is the same 
as other health reviews [13,14]. N.C. reviewed the full text for any potentially relevant 
studies to assess eligibility. Eligible studies met the following criteria: based in SSA, 
original research, any language, qualitative study or quantitative survey and included an 
adult patient-reported barrier or facilitator to ART adherence. Studies were excluded if 
they only focused on initiation to ART in treatment-naïve participants, only utilised a 
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single dose of ART treatment e.g. prophylaxis, only focused on Africans living in a 
non-SSA country or were only reviews. 
Quality Assessment 
N.C. completed quality assessment for all included studies. M.Ah. assessed a random 
sample of 30 (15 qualitative and 15 quantitative). The RATS (Relevance, 
Appropriateness, Transparency, Soundness) measure [15] was used to assess the 
qualitative studies and a measure developed by Hawker and colleagues [16] was used to 
assess the quantitative studies (see supplementary material for further details, 
http://links.lww.com/QAD/B44).  
Data Extraction 
N.C. extracted all the data into a pre-designed excel spreadsheet which was double 
checked for accuracy. After an initial read of all qualitative papers, a list of all key 
barriers and facilitators were identified and were combined into themes. N.C, L.D.H. 
and M.Ab.discussed the themes and any disputes were resolved (see supplementary 
material for further details, http://links.lww.com/QAD/B44). Due to the considerable 
heterogeneity of the studies a meta-analysis was not suitable. 
RESULTS 
A total of 163 papers involving 154 studies were identified for inclusion. The search of 
the 10 databases provided a total of 11,283 citations (see Figure 1). After adjusting for 
duplicates, 6065 citations remained. Of these, 5251 citations were excluded after 
reviewing the title and abstracts. The majority of these were excluded (4928; 93.9%) 
because they were not related to HIV or adherence. The remaining 323 citations (6.2%) 
were excluded based upon other criteria.  
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
The full text of the remaining 799 potentially relevant citations were searched for; 
however, 12 (1.5%) could not be retrieved. The full texts of the remaining 787 papers 
were examined in more detail. Fourteen were excluded (1.8%) because the search had 
identified both published and unpublished formats of the same studies; therefore, the 
published versions were retained. A further 632 papers (80.3%) were excluded based 
upon inclusion and exclusion criteria. From the 141 relevant papers (17.9%) identified, 
134 relevant studies were included. From the additional searching, a further 20 studies 
were identified that met the criteria for inclusion. An acceptable concordance of 91.0% 
was achieved between N.C. and M.Ah. for inclusion of studies. 
Overall, 154 studies were eligible of which 83 were qualitative [17-99], 67 were 
quantitative [100-166] and four were mixed [167-170] which included at least one 
patient-reported barrier or facilitator in both the qualitative and quantitative studies 
included in the paper. Three studies were published in French [116,137,149] and a 
fluent French speaker was utilised to extract the data and translate into English. The 
remaining studies were published in English. 
Description of studies 
A total of 37,175 HIV positive participants were included across all 154 quantitative 
and qualitative studies of which 36,476 were prescribed ART. Within the 87 qualitative 
studies, 3,247 HIV positive participants were included of which 2,824 were prescribed 
ART. Within the 71 quantitative studies, 33,928 HIV positive participants were 
included of which 33,652 were prescribed ART (see supplementary material (Table 3) 
,http://links.lww.com/QAD/B44for a description of each study). 
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Studies were conducted in 24 countries in SSA with six studies including more than one 
country [45,64,84,95,124,130]. More than half the studies (59.7%) were conducted 
across South Africa, Uganda, Ethiopia and Kenya. 
Just over half of the qualitative studies conducted semi-structured in-depth interviews 
(IDI) (49; 56.3 %) [17,20-22,26,27,29,32-37,39-43,45-47,49,51,54-60,62,63,65-67,69-
71,78,81,84,85,87-90,95-97,165] with their HIV positive participants. Eighteen studies 
(20.7%) used focus group discussions (FDG)                                                          
[19,23-25,28,50,53,61,68,73,74,76,77,82,94,98,167,169], 16 used both IDI and FDG 
(18.4%) [18,30,31,38,44,52,64,72,75,79,83,86,92,93,99,170], one used free attitude 
interviews (FAI) and FGD (1.1%) [80], one used group sessions without more detail 
[168], one used IDI and life history and illness narratives [48] and one used digital 
stories [91]. 
The majority of the quantitative surveys (54; 76.1%) were administered by an 
interviewer [100,102,104-109,112,113,115-117,119,121-124,128-130,133-137,139,141-
150,152-166,168,169], five (7.0%) were self-administered [125,126,132,140,151], one 
(1.4%) used an audio computer-assisted self-interview [110] and the remaining studies 
(11; 15.5%) did not specify or it was not clear how the survey was administered 
[101,103,111,114,118,120,127,131,138,167,170]. No studies indicated clearly that there 
was a free response option for participants to report the barriers they experienced (for 
further description on the studies see the supplementary material, 
http://links.lww.com/QAD/B44). 
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Quality assessment 
 
The qualitative studies showed overall high quality, with 98.9% of studies including all 
RATS items related to relevance of study question, 72.4% including the item related to 
appropriateness of qualitative method and 83.5% including all items related to 
soundness of interpretive approach, with the exception of poor transparency of the 
procedure (only 55.0% of studies included all items). In particular, studies required 
more information regarding recruitment (only 23.0% of studies included this), who 
chose not to participate and why (only 20.7% included this), end of data collection 
justification (25.0% included this) and researcher bias (16.1% included this). The 
quantitative studies showed overall fair/good quality (9.2% of studies being assessed as 
good across categories and 65.9% being assessed as fair), with the exception of the 
ethics and bias category (49.3% assessed as poor and 12.7% assessed as very poor). 
Only 5.6% of studies were assessed as good quality in this category, which required 
papers to include explicit details regarding issues of patient confidentiality, sensitivity 
and informed consent. Researchers also were required to be reflexive or be aware of any 
potential bias they may have. A third of studies (32.4%) acknowledged these issues 
without including explicit details; however, the majority either briefly mentioned them 
or did not include them (see supplementary material for further details, 
http://links.lww.com/QAD/B44). 
Barriers 
Forty-three unique patient-reported barriers were identified in 79 (90.8%) of the 
qualitative and 68 (95.8%) of the quantitative studies which we developed into nine 
themes comprising financial constraints, problems with their health provider and other 
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inter-personal relationships, issues regarding medication collection and medication 
taking, treatment-related challenges, problems with their mental health and well-being 
and beliefs about HIV and treatment as well as specific beliefs about ART. See Table 1 
for a list of the themes and both the barriers and facilitators included within each theme 
(see supplementary material for further details including a list of studies which reported 
each factor as well as the frequency of non-adherent participants within each study that 
reported each barrier or facilitator if reported, http://links.lww.com/QAD/B44). 
Facilitators 
Thirty patient-reported facilitators were identified in 76 (87.4%) of the qualitative and 
21 (29.6%) of the quantitative studies. Seventeen facilitators (56.7%) were only 
identified in the qualitative studies. The facilitators are comprised of seven of the same 
themes as the barriers excluding medication collection and treatment-related factors (see 
Table 1). Due to the comparable themes the barriers and facilitators will be described 
together. 
Themes 
There were several factors that impacted adherence related to finance as well as each 
patient‘s health provider. Within the finance theme, in particular not receiving financial 
help was a barrier whereas receiving funds was a benefit. Across studies the fifth most 
reported facilitator was having a good relationship with their health provider (n=22). 
The opposite was identified as a barrier; however, only by a few studies (n=5). 
Four of the five most-reported barriers across all studies were classified into the 
medication taking theme; forgetting (n=76), lack of access to adequate food (n=72), 
stigma and discrimination (n=68) and being outside the house or travelling (n=60). 
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Some of these had comparable facilitators including having reminders to take 
medication (which was the second more reported facilitator (n=55)), having access to 
food or water and carrying ART whilst out of the house although the latter two were 
only identified by a small number of studies.  
Inter-personal relationships included the first and fourth most reported facilitators 
(social support (n=60) and having disclosed their HIV status (n=26)). Both of these 
included comparable barriers (e.g. lack of social support and HIV non-disclosure) 
indicating that an absence of these factors is a barrier to adherence.  
Mental health and well-being was the only theme to include the same factor as both a 
barrier and facilitator; feeling better or healthier after ART treatment. This factor was 
the third most reported facilitator across studies (n=30) although 26 studies also 
reported it as a barrier. Another comparable barrier to feeling better was also reported 
(feeling sick or ill) indicating the opposite can also hinder adherence. Feeling hopeless 
and being hopeful were both reported as comparable factors although only reported in a 
few studies. 
The patients‘ beliefs about HIV and treatments theme also included factors that acted 
both as a barrier and facilitator. Both religious and traditional beliefs and treatments 
were indicated as a barrier to adhering to ART whilst a patient‘s desire to take control of 
their health was a facilitator. Denial of one‘s own HIV status was reported as a barrier 
and had a comparable facilitator of accepting one‘s own HIV status, although these 
were reported by a small number of studies. Specific beliefs about ART also showed to 
have an impact on adherence. The belief in the benefit of ART was reported (n=20) as a 
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facilitator whereas believing ART will not work was reported as a barrier, but only by 7 
studies in comparison.  
Medication collection and treatment-related factors both only included barriers. The 
latter theme included the fourth most reported barrier across studies; side effects (n=67). 
Erratic clinic drug supply and long waiting times were reported by the most studies as a 
barrier to ART adherence in the medication collection theme.  
 
DISCUSSION 
Summary of Evidence 
In this systematic review a total of 43 patient-reported barriers and 30 facilitators to 
ART adherence were identified in 154 studies across 24 SSA countries. Barriers and 
facilitators to ART adherence included: factors related to participants‘ physically taking 
their ART medication (e.g. unable to take their pills without adequate food or using 
reminders to remember to take their pills), factors that impacted participants‘ physical 
or mental health (e.g. feeling sick or feeling better after taking ART), factors related to 
participants‘ relationships with other people (e.g non-disclosure of HIV status to others 
or social support), factors related to finance (e.g. lack of money for HIV care or free 
ART treatment), factors related to participants‘ health provider including all staff (e.g. 
experiencing negative treatment from clinic staff or having a good relationship with 
their health provider), beliefs around HIV and treatments for HIV (e.g. using traditional 
medicines or accepting own HIV status) and beliefs regarding ART (e.g. ART is 
harmful or ART is beneficial). Factors related to collecting medication at the clinic (e.g. 
long waiting times or erratic drug supply) and treatment-related factors (e.g. side effects 
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or pill burden) were only reported as barriers to ART adherence. One factor was both a 
barrier and facilitator (e.g. feeling better after taking ART) which emphasises 
medication adhering behaviour is not universal and it is necessary to explore this 
individually. The most frequently identified barriers across studies and methodologies 
were forgetting, lack of access to adequate food, stigma and discrimination, side effects 
and being outside the house or travelling. The most frequently identified facilitators 
across studies and methods were social support, using reminders, feeling better or 
heathier after taking ART, disclosing their HIV status and having a good relationship 
with a health provider. This review helps identify the range and frequency of factors 
that impact ART adherence for patients within a variety of different settings in SSA.  
Other systematic reviews have focused on specific types of adherence barriers including 
geographic and transport-related barriers in SSA [171], food insecurity [172] and 
depression and alcohol use in SSA [173]. These reviews are useful because they go in-
depth into one type of barrier and they may focus on other HIV outcomes other than 
adherence [171]; however, this review is necessary to give an overview of the many 
factors that affect ART adherence in SSA.   
Frequency across studies does not necessarily equate with importance for individuals; 
therefore, the most reported factors may not have the greatest impact upon adherence. 
Unfortunately the low number of studies that included the non-adherent within-study 
frequencies means it is difficult to compare the impact of these on adherence. Future 
studies should include these to allow researchers to ascertain not only the range of 
factors that affect adherence but the impact of each.  
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This review identified 26 barriers that were not previously reported in SSA in the 
previous systematic review [3] including traditional medicines, religious beliefs or 
treatments, lack of access to food and sharing medication. These need to be 
acknowledged when working with people living with HIV in SSA. The five most 
frequently reported facilitators were included in the previous review [3] showing there 
is similarity between patients in HIC and LMIC; however, several others were identified 
that had not been previously noted e.g. financial aid, access to food and water and 
religious beliefs. This further confirms that there are factors that may be more 
applicable to LMIC that therefore need particular consideration when designing 
interventions to improve ART adherence.  
Understanding and being aware of these are important for policy makers, researchers 
and health professionals. Although patients denied missing ART doses to their health 
professional, if a barrier measure was used, patients would then reveal non-adherence 
by indicating the barriers that prevent them from adhering [174]. Having a list of 
barriers that are applicable to the context is essential. There are some differences 
between HIC and LMIC and this should be reflected in the provisions available for 
patients. Although general and HIV-specific measures for barriers to adherence do 
currently exist [175-179], none encompass the wide range of reasons identified in this 
review. Developing or adapting a measure that can be utilised by health professionals in 
SSA is necessary. In particular, the most commonly used self-report HIV adherence 
measure [180] (Adult AIDS Care Trials Group [AACTG]) includes a ‗reasons for non-
adherence‘ subscale [175] which needs to be adapted if used in SSA to include all 
relevant factors. To our knowledge, there is not a similar measure for facilitators and 
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research needs to explore whether assessing the facilitators may be equally as helpful as 
the barriers to reach the level of desired adherence.  
Immediate treatment initiation after diagnosis has been shown to have more positive 
HIV outcomes than later [181,182] thus may become the recommended start date 
globally. There are debates in the literature about the practicalities associated with 
immediate ART initiation [183] including increased burden on the health care system, 
increased frequency of risk behaviours when receiving ART and ethical issues such as 
resource allocation in low-resource settings [183]. The impact of certain barriers may 
increase, such as the factors associated with health care; therefore, the need to enhance 
the facilitators will become greater.  
Future research needs to help identify the barriers and facilitators that have the greatest 
impact on adherence and help develop interventions based upon these. Within SSA, 
there have been several interventions focused on helping participants remember their 
medication whereas less have focused on lack of food or stigma [184]. Research needs 
to explore whether these other interventions would have a greater influence on 
adherence. Additionally, the focus on adherence interventions in SSA have often been 
observational and more randomised control trials (RCT) are required [184].  
Limitations 
Although efforts were made to include all eligible studies, it is possible that not all 
studies exploring barriers and facilitators to ART adherence in SSA were included as 
research from resource-constrained settings may be less likely to be published or not 
indexed in the major databases [185]. The studies are not easily compared due to the 
heterogeneity of how factors and adherence were measured. There was a great variety of 
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within study frequency measurement; therefore, only studies that included the frequency 
of reporting within non-adherent participants were included. Also some studies 
combined separate factors into one e.g. financial problems, so it was not possible to 
extract the individual factors. The quality of the studies seemed generally fair; however, 
there were areas of poor quality. Since two measures were utilised in quality assessment 
it is not easy to compare the quality across both qualitative and quantitative studies.  
The majority of the qualitative studies identified both barriers and facilitators whereas 
the majority of the quantitative studies only identified barriers. This bias may have 
prevented certain facilitators from being identified. Barrier measures or adapted 
versions [175,177,186-189] were utilised in some surveys which may have caused 
certain barriers to be reported more frequently; however, other important barriers may 
have been missed because they were not included.  
Conclusions 
This review highlights the range and frequency of barriers and facilitators that affect 
ART adherence in HIV patients in SSA. Research needs to help identify which factors 
have the greatest impact on adherence and develop interventions accordingly. Measures 
need to be developed or adapted for SSA to include all the relevant factors. 
Interventions need to be developed that aim to reduce the barriers and enhance the 
facilitators. By understanding and being able to identify what hurdles a patient 
experiences and how certain aspects may encourage them to adhere, the focus is now on 
using this information to help patients achieve optimum ART outcomes. 
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FIGURE 1 FLOWCHART 
 
 
Duplicates excluded = 5218 
Total number of records after duplicates excluded = 6065 
Excluded based upon title and abstract = 5251 
 Not relating to HIV and/or ART adherence = 4928 
 Not focused on adherence barriers or facilitators = 80 
 Not in SSA = 8 
 Not qualitative/survey study = 80 
 Review = 40 
 Not original research = 33 
 Included participants under 18 = 58 
 Not continuous treatment or treatment naive = 24 
Number of records after title and abstract shifting = 799 
Excluded based upon full text = 632 records 
 Not related to ART adherence = 161 
 Not relating to barriers or facilitators = 156 
 Not patient reported = 40 
 No patient-reported barriers or facilitators = 64 
 Conference abstract (unable to contact authors) = 7 
 Include participants under 18/not specified age range = 67 
 Book reviews = 2 
 Not original research = 42 
 Not qualitative/survey study = 16 
 Not continuous treatment or treatment naïve/ not sure if 
continuous treatment = 10 
 Systematic/Literature Review = 39 
 Only patients not receiving ART = 13 
 Participants did not have HIV/AIDS = 13 
 Did not specify whether participants had HIV/AIDS = 2 
 Not in SSA = 12 
 
Could not access  
full text = 12 
Abstract/Dissertation/ 
Report results published  
and in review = 14 
All relevant studies = 154 (163 papers) 
(Qual = 83, Quant = 67, Mixed = 4) 
 
 
Additional relevant studies 20 (20 records) 
(Qual = 8, Quant = 10, Mixed = 2) 
Relevant Studies = 134 (141 records) 
(Qual = 75, Quant = 57, Mixed = 2) 
 
 
Total number of records = 11283 
 Cochrane = 384 
 African Index Medicus = 29 
 ASSIA = 218 
 IBSS = 233 
 CINAHL = 1081 
 Medline = 3069 
 PsycINFO = 544 
 PsycARTICLES = 128 
 Embase = 3537 
 Global Health = 2060 
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TABLE 1 BARRIERS AND FACILITATORS 
Themes Barriers (n of studies that reported factor) Facilitators (n of studies that reported factor) 
Financial Lack of money for transport to ART 
clinic (32) 
Lack of money for HIV care (19) 
Do not want to lose disability grant (6)* 
Grant or livelihood support (5)* 
Free ART treatment (4) 
Health Provider Dissatisfaction with HIV/ART 
information provided (17) 
Experienced negative treatment from 
clinic staff (10) 
Unable to gain attention from staff (9) 
Poor relationship with health  
provider (5)* 
Good relationship with health provider (22)* 
Receiving counselling and/or teaching (17) 
Medication 
Taking 
Forgetting (76)
a
 
Lack of access to adequate food (72)
b
* 
Stigma and discrimination (68) 
Outside house or travelling (60)
c
 
Being busy (30) 
Run out of ART (26) 
Sleeping (22) 
Difficulty taking ART in private (17)
a
 
Change in daily routine (15) 
No access to liquids (6)
a
* 
Reminders (55) 
Having a routine (9) 
ART packaging (7) 
Access to food and/or water (6)* 
Carrying ART whilst out of the house (5) 
 
Inter-Personal 
Relationships 
Lack of social support (22)* 
Sharing or selling ART (7) 
HIV non-disclosure (21)* 
Gender (wives have lack of autonomy) 
(6) 
 
Social support (60)
a
* 
Having disclosed HIV status (26)* 
Want to live and take care of children (21) 
Attending a support group (11) 
Seeing others improve on ART (6) 
Want to look healthy to others (5) 
Staying away from negative relationships (2) 
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Mental Health 
and Well-Being 
Feeling sick or ill (30)* 
Using alcohol or other substances (27)
a
 
Feeling better or healthier (26)** 
Low mood or stress (22)
a
 
Feeling hopeless (7)* 
Feeling lonely (4) 
 
Feeling better or healthier (35)*** 
Being able to work again (13) 
―Normalisation‖ – feeling the same as others 
or same as before HIV (8) 
Fewer HIV/AIDS related illnesses (8) 
Prayers or faith in God (8) 
Being hopeful (6)* 
Beliefs about 
HIV and 
Treatment 
Religious beliefs or treatments (27)
a
 
Traditional beliefs or medicines (20) 
Fear of cause of HIV (6) 
Denial of HIV status (4)* 
Want to take control of their health (13) 
Improved knowledge and understanding of 
HIV/ART (10) 
Accept own HIV status (7)* 
Beliefs about 
ART 
Negative attitude towards treatment  
regime (19) 
ART will not work (7)* 
ART is harmful (7) 
Lack of motivation to take ART (7) 
Should not mix ART with other 
treatments (4) 
Belief in ART benefit (20)* 
Do not want to be ill again (14) 
Adherence self-efficacy (8) 
ART helps you look healthy to others (5) 
God provided ART (4) 
Medication 
Collection 
Erratic clinic drug supply (22) 
Long clinic waiting times (13)
a
 
Long distance to the clinic (8) 
Unable to get to clinic due to work  
constraints (7) 
 
Treatment-
Related Factors 
Side effects (67)
c
 
Pill burden (20) 
Problem with physical characteristics of  
Pills (4) 
 
a
 One mixed-methods study identified the barrier in both the qualitative and quantitative components 
b
Three mixed-methods studies identified the barrier in both the qualitative and quantitative components 
c
Two mixed-methods studies identified the barriers in both the qualitative and quantitative components 
* Comparable barriers and facilitators across themes 
** Same factor as both a barrier and facilitator 
*** Same factor as well as a comparable factor 
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